perfusion and interstitial transport conditions). By influencing the local transport environment without changing the drug formulation, RayBalance aims to accelerate time to onset, reduce pharmacokinetic variability, and improve dosing consistency for high-impact subcutaneous therapies, including insulin, GLP-1s, and other biologics.

RayBalance is advancing a staged validation program to quantify performance across relevant drug classes and patient-relevant conditions, with the goal of enabling partnerships with pharmaceutical, biosimilar, and drug delivery stakeholders. The company is led by CEO Darrel Drinan.